Affected Systems |
|
|
|
|
|
|
cellular
|
|
√
|
|
|
√
|
decreased mast cell degranulation
|
|
√
|
|
|
|
impaired macrophage phagocytosis
|
|
√
|
|
|
√
|
growth/size/body
|
|
|
√
|
|
|
enlarged spleen
|
|
|
√
|
|
|
increased spleen weight
|
|
|
√
|
|
|
hematopoietic system
|
√
|
√
|
√
|
√
|
√
|
enlarged spleen
|
|
|
√
|
|
|
increased spleen weight
|
|
|
√
|
|
|
decreased susceptibility to autoimmune hemolytic anemia
|
|
√
|
|
|
|
abnormal leukocyte cell number
|
√
|
|
|
|
|
increased neutrophil cell number
|
√
|
|
|
|
|
increased B cell number
|
|
|
√
|
|
|
increased activated T cell number
|
|
|
√
|
|
|
abnormal mast cell physiology
|
|
|
|
√
|
|
decreased mast cell degranulation
|
|
√
|
|
|
|
abnormal neutrophil physiology
|
√
|
|
|
|
|
impaired neutrophil recruitment
|
√
|
|
|
|
|
impaired natural killer cell mediated cytotoxicity
|
|
√
|
|
|
|
abnormal macrophage physiology
|
|
|
|
√
|
|
impaired macrophage phagocytosis
|
|
√
|
|
|
√
|
immune system
|
√
|
√
|
√
|
√
|
√
|
enlarged spleen
|
|
|
√
|
|
|
increased spleen weight
|
|
|
√
|
|
|
decreased susceptibility to autoimmune hemolytic anemia
|
|
√
|
|
|
|
abnormal leukocyte cell number
|
√
|
|
|
|
|
increased neutrophil cell number
|
√
|
|
|
|
|
increased B cell number
|
|
|
√
|
|
|
increased activated T cell number
|
|
|
√
|
|
|
abnormal mast cell physiology
|
|
|
|
√
|
|
decreased mast cell degranulation
|
|
√
|
|
|
|
abnormal neutrophil physiology
|
√
|
|
|
|
|
impaired neutrophil recruitment
|
√
|
|
|
|
|
impaired natural killer cell mediated cytotoxicity
|
|
√
|
|
|
|
abnormal macrophage physiology
|
|
|
|
√
|
|
impaired macrophage phagocytosis
|
|
√
|
|
|
√
|
abnormal dendritic cell antigen presentation
|
|
√
|
|
|
|
abnormal type I hypersensitivity reaction
|
|
√
|
|
|
|
increased susceptibility to type I hypersensitivity reaction
|
|
|
|
√
|
|
decreased susceptibility to type II hypersensitivity reaction
|
|
√
|
|
|
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
√
|
|
|
|
|
decreased susceptibility to induced arthritis
|
√
|
|
|
|
|
increased anti-chromatin antibody level
|
|
|
√
|
|
|
increased anti-double stranded DNA antibody level
|
|
|
√
|
|
|
increased anti-histone antibody level
|
|
|
√
|
|
|
increased anti-single stranded DNA antibody level
|
|
|
√
|
|
|
mortality/aging
|
|
|
N
|
|
|
mortality/aging
|
|
|
N
|
|
|
skeleton
|
√
|
|
|
|
|
decreased susceptibility to induced arthritis
|
√
|
|
|
|
|